Jeff Hall

The artificial intelligence (AI) software Saige-Density™ reportedly provides automated assessment of breast density during mammography exams.

Reportedly the first targeted molecular imaging agent to provide intraoperative illumination of lung cancer, Cytalux (pafolacianine) helped identify clinically significant events in more than 50 percent of patients undergoing surgery for confirmed or suspected pulmonary nodules, according to Phase 3 trial data presented earlier this year at the American Association for Thoracic Surgery Annual Meeting.

In addition to summary sensitivity and specificity of 92 percent and 91 percent respectively for characterization of indeterminate adnexal lesions, the meta-analysis on pelvic magnetic resonance imaging (MRI) revealed higher summary malignancy rates for O-RADS MRI 4 and 5 lesions than predicted.

Employing an artificial intelligence (AI) tool to quantify airway-to-artery (AAR) diameter ratios on chest computed tomography (CT), researchers found the percentage of airways with an AAR greater than 1 was associated with increased pulmonary exacerbations in ever-smokers.

In a study of nearly 18,000 men who had prostate cancer screening, researchers found the use of pre-biopsy magnetic resonance imaging (MRI) for those with elevated prostate-specific antigen (PSA) levels and reserving MRI-targeted biopsy for those with PI-RADS scores of 3 to 5 reduced the risk of detecting clinically insignificant cancers by half.

In a recent video interview from the Radiological Society of North America (RSNA) conference, Tessa Cook, MD, PhD discussed new research on automated de-identification in radiology reports and the potential of artificial intelligence (AI) and natural language processing (NLP) to help address time-consuming challenges in the radiology workflow.

In a new study based on five- to six-year follow-up data from over 650,000 children and young adults who had at least one computed tomography (CT) exam prior to the age of 22, researchers found a “strong dose-response relationship” between increased CT radiation exposure and brain cancer.

The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.

The EchoGo® Heart Failure device reportedly has an 87.8 percent sensitivity rate and an 83 percent specificity rate for diagnosing heart failure with preserved ejection fraction, an increasingly prevalent but frequently misdiagnosed condition.

One study showed use of the Aorta-CAD cloud-based software led to a 62 percent reduction of missed aortic calcification that suggested aortic atherosclerosis.

For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).

In a recent video interview, Susan Holley, MD discussed key findings from a large retrospective longitudinal study, presented at the recent Radiological Society of North America (RSNA) conference, which found that an emerging artificial intelligence (AI) model was over 24 percent more consistent than radiologist assessment of breast density.

In a recent lecture at the Radiological Society of North America (RSNA) conference, Wendy DeMartini, MD, discussed a variety of preliminary proposed changes to the Breast Imaging Reporting and Data System (BI-RADS) for breast magnetic resonance imaging (MRI) examinations.

In a recent video interview, Raymond Y. Kwong, MD, discussed his clinical experience with the Vista.ai (formerly HeartVista) One Click MRI software and recent research, presented at the Radiological Society of North America (RSNA) conference, that revealed a 31 percent decrease in cardiac MRI scan times for patients with cardiomyopathy or structural heart disease.

Ultra-low-dose computed tomography (ULDCT) may have similar efficacy as low-dose CT (LDCT) for detecting a variety of pulmonary conditions in people with current or past smoking histories, but had poor detection of ground glass opacification lesions, according to a recent prospective study presented at the Radiological Society of North America (RSNA) conference.

Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.

Enhancements for the BodyTom 64 Point-of-Care Mobile Computed Tomography (CT) Scanner include upgraded cross-sectional imaging capabilities and a Linux operating system.

Offering more than 70 clinical applications, the next-generation edition of the Advanced Visualization Workspace reportedly includes enhanced liver analysis and artificial intelligence (AI)-powered scoring of early brain infarction noted on computed tomography (CT) scans for patients with ischemic stroke.

New research suggests the Viz Aortic Dissection Algorithm has a 94.2 percent sensitivity rate for detecting aortic dissection on computed tomography (CT) angiography.

Emphasizing the benefits of annual lung cancer screening with low-dose computed tomography (CT), researchers noted high 20-year survival rates for a variety of early-stage lung cancer tumor presentations, including a 100 percent survival rate for those with non-solid or partly solid cancerous nodules.

COVID-19 may cause changes in the brain stem and frontal lobe that could lead to fatigue, impacts in motor signal processing, insomnia, and depression, according to emerging research recently presented at the Radiological Society of North America (RSNA) annual conference in Chicago.

In a study of over 800 women with breast cancer, researchers found that African-American women had a higher rate of ductal carcinoma in situ (DCIS) and were less likely to have irregular masses in screening exams in comparison to non-Latina White women.

Emerging research showed the combination of contrast-enhanced ultrasound (CEUS) with perfluorobutane and modified 2017 LI-RADS criteria had comparable sensitivity, specificity, and accuracy to current magnetic resonance imaging (MRI) and computed tomography (CT) approaches to detecting hepatocellular carcinoma (HCC) lesions.

New magnetic resonance imaging research shows earlier brain aging in middle-age Black individuals with researchers suggesting that cumulative exposure to stress over socioeconomic and environmental adversities may be a key contributing factor.

GE Healthcare’s DaTscan is reportedly the first radiopharmaceutical tracer agent approved by the Food and Drug Administration (FDA) for use in patients with suspected dementia with Lewy bodies.

A new computed tomography study reveals that people who smoke marijuana may have a 70 percent higher risk of developing emphysema than non-smokers, and an age-matched subgroup analysis suggests marijuana use could be associated with a 26 percent higher risk of emphysema in comparison to tobacco-only smoking.

The Sonimage MX1 Platinum device reportedly offers a number of features to provide optimal ultrasound image resolution in a variety of point-of -care settings.

Emerging research has revealed findings on diffusion magnetic resonance imaging (MRI) correlational tractography that may help neuroradiologists differentiate between autism spectrum disorder (ASD) and developmental coordination disorder (DCD).

A new study of nearly 17 million emergency department (ED) visits by Medicare beneficiaries between 2005 and 2020 revealed the presence of non-physician practitioners (NPPs) was associated with a 5.3 percent increase in imaging.

Findings from a recent multinational phase III trial demonstrated that the investigational agent TLX250-CDx had an 86 percent sensitivity rate for detecting clear cell renal cell carcinoma via positron emission tomography/computed tomography (PET/CT).